ArticleVeterinary dermatology2026
Assessing D-Squame as a Minimally Invasive Technique to Evaluate the Cutaneous Immune Response mRNA in a Dog Model of Canine Atopic Dermatitis.
Article in Veterinary dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCanine atopic dermatitis (cAD) is a multifactorial, inherited skin disease, estimated to affect ≤ 15% of dogs. Studies of skin messenger mRNA in cAD currently use invasive methods, including blood sampling and biopsy collection, whilst advances in human atopic dermatitis study methodology have demonstrated reliable use of minimally invasive skin sampling techniques for similar objectives.
objectivesTo validate the use of the minimally invasive D-Squame (tape stripping; TS) method for skin mRNA analysis in dogs, and to investigate the association of highly dysregulated mRNAs with clinical response in a canine model of cAD. ANIMALS: Eight healthy beagles. MATERIALS AND
methodsDogs were epicutaneously sensitised twice weekly for 7 weeks (49 days) using house dust mites (HDM; Dermatophagoides farinae). The clinical response of individual dogs to sensitisation was categorised as low, average, or high. On Day 49, D-Squame TS samples were obtained from sensitised and nonsensitised sites from each dog, and transcriptomic analyses were performed. RNA-Seq data analyses were performed using R and Bioconductor with default parameters.
resultsComparing sensitised and control sites, 210 of 12,545 expressed genes were most differentially expressed (fold-change ≥ 2, p ≤ 0.05). CD2, CD3D/E, CD209 (T cell), IL13, TNFRSF4, CCL17 (T helper 2 cell [Th2]), FCER1A and CD80 (dendritic cells) were among the top 50 most dysregulated genes significantly correlating with sensitisation. Dysregulation of several key mRNAs, including those involved in the Th2 pathway, correlated with clinical response. CONCLUSIONS AND CLINICAL RELEVANCE: This proof-of-concept study using a minimally invasive method to investigate skin mRNA in cAD lesions enables ethical research of immune biomarkers involved in cAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.